This is not surprising, since it is known that approximately 40% of patients with clinically definite MS and approximately 20% of clinically isolated syndrome (CIS) patients show intrathecal IgM synthesis, as demonstrated by either IgM OCBs or by the IgM index/IF [13,14]. The gene discussed is CD40LG; the disease is in situ carcinoma.